Silas Inman

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @SilasInman, LinkedIn, sinman@mjhlifesciences.com.

Articles

Pirtobrutinib Shows High Response Rates in Heavily Pretreated Waldenström Macroglobulinemia

December 11th 2022

The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.

Elranatamab Shows Promise for Penta/Triple-Refractory Myeloma

December 10th 2022

Treatment with the CD3/BCMA bispecific antibody elranatamab elicited an objective response rate by blinded independent central review of 61.0% in patients with penta- or triple-class refractory multiple myeloma who had not received a prior BCMA-targeted therapy.

Frontline Dostarlimab Shows Superior PFS vs Pembrolizumab in NSCLC

December 8th 2022

Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.

Sotorasib Significantly Improves PFS Vs Docetaxel for KRAS G12C–Mutated NSCLC

September 12th 2022

Sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of progression or death by 34% compared with docetaxel for patients with previously treated non–small cell lung cancer with KRAS G12C mutations.

Lenvatinib/Pembrolizumab Combo Provides Continued OS, PFS Benefit in Advanced RCC

September 11th 2022

Lenvatinib plus pembrolizumab showed sustained overall survival and progression-free survival benefit across poor- and intermediate-risk subgroups of patients with advanced renal cell carcinoma.

Blood-based Assay Demonstrates Positive Prognostic Value for Solid and Liquid Tumor Detection

September 11th 2022

A pan-tumor blood-based assay demonstrated a specificity of 99.1% and positive predictive value of 38.0% and resulted in a diagnosis of cancer in 35 individuals.

Neoadjuvant T-VEC Plus Surgery Demonstrates Long-Term Efficacy in Resectable Melanoma

September 10th 2022

Neoadjuvant talimogene laherparepvec plus surgery provided sustained, durable improvements in efficacy vs surgery alone in patients with resectable stage IIIB to IVM1a melanoma.

TILs Demonstrate Improved PFS Vs Ipilimumab in Unresectable Melanoma

September 10th 2022

A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC

September 10th 2022

First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.

Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma

June 7th 2022

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.

Radiotherapy Unnecessary for Some Luminal A Breast Cancers

June 7th 2022

Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.

Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC

June 5th 2022

Treatment with fam-trastuzumab deruxtecan-nxki doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer.

CT041 CAR T-cell Therapy Elicits Manageable Toxicity and Durable Response in Gastric/GEJ Cancer

June 5th 2022

CT041, a Claudin18.2–specific CAR T-cell therapy, demonstrated a manageable safety profile in patients with previously treated, CLDN18.2-positive advanced gastric/gastroesophageal junction cancer, with a majority of patients achieving partial response or stable disease.

Trastuzumab Deruxtecan Remains Safe and Effective Option for Metastatic Breast Cancer

June 4th 2022

Updated data from a safety analysis of the phase 3 DESTINY-Breast03 study confirmed the tolerability of trastuzumab deruxtecan among patients with with HER2-positive unresectable or metastatic breast cancer.

ctDNA Demonstrates Efficacy as Treatment-Decision Tool for Adjuvant Chemotherapy in Colon Cancers

June 4th 2022

Guided approaches leveraging circulating tumor DNA status can reduce the number of patients who receive adjuvant chemotherapy without the risk of lowering recurrence-free survival rates for some patients with stage II colon cancer.

Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma

June 4th 2022

Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.

Adjuvant Everolimus Displays RFS Benefit in Very High-Risk RCC

June 4th 2022

Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma.

Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma

June 3rd 2022

Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma

April 25th 2022

The novel allogeneic CAR-engineered natural killer cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

Biomarkers Allow for Tailoring TNBC Treatments

March 5th 2022

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.